Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Pedagogiczna Biblioteka Wojewódzka im. Komisji Edukacji Narodowej w Lublinie Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaPedagogiczna Biblioteka Wojewódzka im. Komisji Edukacji Narodowej w Lublinie
Zmień bibliotekę

Wyszukujesz frazę "Bucsics, Anna" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-6 z 6
    Autorzy:
    Novakovic, Tanja
    Sauermann, Robert
    Tomek, Dominik
    Yfantopoulos, John
    Bossell, Simone
    Bochenek, Tomasz
    Zara, Corine
    Sermet, Catherine
    Campbell, Stephen
    Oluka, Margaret
    Mellen, Oyvind
    Selke, Gisbert
    Meshkov, Dimitry
    Haycox, Alan
    Martin, Antony P.
    Petrova, Guenka
    Jakupi, Arianit
    Mitkova, Zornitsa
    Pomorski, Maciej
    Ferrario, Alessandra
    Hoxha, Iris
    Matsebula, Zinhle
    Furst, Jurij
    Magnusson, Einar
    Rothe, Celia C.
    Kwon, Hye-Young
    Godman, Brian
    Guerra Jr., Augusto Alfonso
    Laius, Ott
    Diogene, Eduardo
    Meyer, Johanna C.
    Gulbinovic, Jolanta
    Wattermark, Bjorn
    Mardare, Ileana
    Bucsics, Anna
    Kourafalos, Vasileios
    Fadare, Joseph O.
    Wladysiuk, Magdalene
    Achniotou, Gnosia
    Simoens, Steven
    Salem, Ahmed
    Joppi, Roberta
    Gad, Mohamed
    Kurdi, Amanj
    Vella Bonanno, Patricia
    Kalemeera, Francis
    Timoney, Angela
    Massele, Amos
    Malmstrom, Rickard E.
    Oortwijn, Wija
    Hill, Andrew
    Markovic-Pekovic, Vanda
    Opis:
    Introduction: There is continued unmet medical need for new medicines across countries especially for cancer, immunological diseases, and orphan diseases. However, there are growing challenges with funding new medicines at ever increasing prices along with funding increased medicine volumes with the growth in both infectious diseases and non-communicable diseases across countries. This has resulted in the development of new models to better manage the entry of new medicines, new financial models being postulated to finance new medicines as well as strategies to improve prescribing efficiency. However, more needs to be done. Consequently, the primary aim of this paper is to consider potential ways to optimize the use of new medicines balancing rising costs with increasing budgetary pressures to stimulate debate especially from a payer perspective. Methods: A narrative review of pharmaceutical policies and implications, as well as possible developments, based on key publications and initiatives known to the co-authors principally from a health authority perspective. Results: A number of initiatives and approaches have been identified including new models to better manage the entry of new medicines based on three pillars (pre-, peri-, and post-launch activities). Within this, we see the growing role of horizon scanning activities starting up to 36 months before launch, managed entry agreements and post launch follow-up. It is also likely there will be greater scrutiny over the effectiveness and value of new cancer medicines given ever increasing prices. This could include establishing minimum effectiveness targets for premium pricing along with re-evaluating prices as more medicines for cancer lose their patent. There will also be a greater involvement of patients especially with orphan diseases. New initiatives could include a greater role of multicriteria decision analysis, as well as looking at the potential for de-linking research and development from commercial activities to enhance affordability. Conclusion: There are a number of ongoing activities across countries to try and fund new valued medicines whilst attaining or maintaining universal healthcare. Such activities will grow with increasing resource pressures and continued unmet need.
    Dostawca treści:
    Repozytorium Uniwersytetu Jagiellońskiego
    Artykuł
      Wyświetlanie 1-6 z 6

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies